Clinical studies

Studies beyond compare

National Institute for Health and Care Excellence (NICE)* provides national guidance and advice to improve health and social care:

  • NICE evaluated the quality of data for dermal substitute studies that included cure rate at 12 weeks versus standard care in diabetic foot ulcers
  • GRAFIX Cryopreserved Placental Membrane had the highest overall effects vs. SOC and was the only dermal substitute determined to have "high quality evidence" with "no serious risk of bias".

50% reduction in wound recurrence (7,680 Medicare claims) over 12 months after patients received GRAFIX Membrane to manage their DFUs

See the study

62% of DFUs (n=97) closed with GRAFIX Membrane at 12 weeks vs. 21% with standard of care alone (p=0.0001)24,25

See the study

59% of complex DFUs (n=27) closed with GRAFIX Membrane at 16 weeks26

See the study

53% of VLUs that failed to close with 12 weeks SOC went on to close with GRAFIX Membrane + standard of care (p<0.001)27

See the study

59% of DFUs (n=350) closed with GRAFIX Membrane30

See the study

76% of chronic wounds (n=67) closed with GRAFIX Membrane at 12 weeks34

See the study

63% of chronic wounds (n=40) closed with GRAFIX Membrane29

18% of chronic wounds (n=39) closed with EpiFix™ (p<0.0001)29

See the study

59% of chronic wounds (n=98) achieved complete wound closure with GRAFIX PL Membrane28

See the study

View a summary of our clinical studies here.